CD274 and non-small cell lung carcinoma: Immune checkpoint blockade (ICI) using PD‐L1 or PD‐1 inhibitory antibodies represents a breakthrough for the treatment of non‐small‐cell lung cancer (NSCLC) patients with metastasis where no targetable mutation is revealed [1, 2, 3].